LNTH
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Lantheus doses the first patient in the registrational Phase 2/3 SPARROW trial in prostate cancerSep 28, 2026
- Lantheus receives final FDA approval for BRAVNETSA, a radiopharmaceutical deemed bioequivalent and therapeutically equivalent to LUTATHERA for GEP-NETsSep 22, 2026
- Lantheus obtained FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent to LUTATHERA®Mar 2, 2026
- Lantheus announces FDA grants PDUFA date for LNTH-2501 (Ga 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive neuroendocrine tumorsOct 30, 2025
- Lantheus announces FDA acceptance of new drug application for MK-6240, a PET imaging agent targeting Tau in Alzheimer's diseaseOct 28, 2025